Disclosed is the use of a) neurogenic CNS lipids b) L-amino acids arginine (Arg) or lysine (Lys) and leucine (Leu), c) trace elements chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V), and tungsten (W), and d) folic acid for the manufacture of a pharmaceutical composition for treating or preventing sterile inflammation causing rheumatism.